Introduction
The urokinase-type plasminogen activator converts the zymogen plasminogen into plasmin a serine protease with broad substrate speci®city (Nielsen et al., 1988; Robbins et al., 1967) . Several studies have shown that urokinase can bind to a 55 ± 60 kDa heavily glycosylated, disul®de linked, cell surface receptor (u-PAR) speci®cally and with high anity (K D^0 .5 nM) (Stoppelli et al., 1986; Vassalli et al., 1985) . This receptor is comprised of three similar repeats approximately 90 residues each Riittinen et al., 1996) the ®rst of which is required for the binding of urokinase and the last which is anchored to the cell membrane via a glycosyl-phosphatidylinositol chain . The 7 exon human u-PAR gene has been located to chromosome 19q13 (Vagnarelli et al., 1992; Casey et al., 1994) and is transcribed into a 1.4 kb mRNA or an alternatively spliced variant which lacks the carboxy-terminal membrane attachment peptide sequence (Roldan et al., 1990; Pyke et al., 1993) . Although up to 1500 base pairs of upstream sequence, which includes putative binding sites for PEA3, AP-2, Sp1 and NF-kB but no potential TATA or CAAT boxes, has been determined, this and other laboratories have shown that a proximal region of the promoter containing 398 base pairs of sequence is sucient for the constitutively elevated and the phorbol ester-inducible expression of the gene in diverse cell types (Soravia et al., 1995; Wang et al., 1995; Lengyel et al., 1996) .
The u-PAR has been implicated in tissue remodeling in a number of physiological and pathological processes such as re-epithelialization in skin wounds and tumor cell invasion (Crowley et al., 1993; Kook et al., 1994) . Romer et al. (1994) demonstrated, using in situ hybridization, that mRNA encoding this receptor was present in keratinocytes at the leading edge of regenerative epithelial outgrowths. The signal was strongest in the keratinocytes just beginning to move 12 h after wounding. Likewise, wounding of an endothelial cell monolayer triggers a rapid and sustained increase in u-PAR expression at the surface of the migrating cells and this increase is mediated by endogenous ®broblast growth factor (FGF) (Pepper et al., 1993) . In a number of cancers, the expression of the u-PAR is required for the invasive phenotype (Quattrone et al., 1995; Kariko et al., 1993; Kook et al., 1994) and for colon cancer a high u-PAR level portends a low 5 year survival rate (Ganesh et al., 1994) . Overexpression of a human u-PAR cDNA increased the ability of human osteosarcoma cells to penetrate a barrier of reconstituted basement membrane (Kariko et al., 1993) . Conversely, a study by Kook et al. (1994) demonstrated that the expression of an antisense u-PAR cDNA in HEp3 squamous cell carcinoma cells decreased their invasiveness into a modi®ed chorioallantoic membrane. The u-PAR promotes tissue remodeling in at least three ways. Firstly, it accelerates extracellular matrix degradation by increasing the rate of plasmin formation at the cell surface (Ellis et al., 1991; Higazi et al., 1995) . Secondly, the binding site can internalize urokinase that is covalently linked to its physiological inhibitor PAI-1 . Thirdly, the receptor can interact with vitronectin thereby modulating cellular adhesion (Wei et al., 1994; Nip et al., 1995) .
Our previous studies have shown that u-PAR display is elevated (410 5 /cell) in an in vitro invasive colon cancer cell line (RKO) when compared with the poorly invasive GEO (410 4 /cell) colon cancer cells (Hollas et al., 1991; Schlechte et al., 1989) . Further, the increased u-PAR display by the RKO cells is a direct consequence of transcriptional activation of the gene as shown by nuclear run on experiments (Wang et al., 1994) . Other investigators have reported that u- Equal amounts of protein extract were subjected to SDS ± PAGE and the resolved proteins transferred to nitrocellulose. The ®lter was probed with an antibody, which crossreacts with human ERK1 and ERK2, and the bands visualized by ECL. Molecular weight markers are indicated to the left. (b) and (c) Equal amounts of extracted protein in the cell supernates were reacted with an anti-ERK1/ERK2 antibody and protein-A Sepharose, and the precipitate electrophoresed in a SDS ± PAGE gel containing myelin basic protein (MBP). The gel was washed with 2-propanol and treated sequentially with guanidine HCl and a buer containing Tween 40/2-mercaptoethanol. Phosphorylation of MBP was carried out by incubating the gel with [g 32 P]ATP. After incubation, the gel was washed and autoradiographed for 2 (b) or 16 h (c). (d) Cells (50 000) were plated on day 0 and proliferation rate assessed at the indicated times with MTT. The experiments were repeated twice or more PAR expression is up-regulated by a variety of growth factors (EGF, FGF, HGF/SF) and by phorbol ester (Mignatti et al., 1991; Lund et al., 1995; Jeers et al., 1996) . Since all of these agents increase extracellular signal-regulated kinase (ERK) activity (Fabian et al., 1993; Bogoyevitch et al., 1994; Tsai et al., 1995) , the objective of the current study was to determine the role of ERK1 and ERK2 in regulating u-PAR expression in these two colon cancer cell lines. The ERKs, which are mitogen-activated protein kinases (MAPKs), modulate the activity and/or synthesis of a diverse set of transcription factors involved in inducible gene expression (Gille et al., 1992; Rao and Reddy, 1993; Pulverer et al., 1991; Agarwal et al., 1995; Bogoyevitch et al., 1995; Janknecht, 1996; O'Hagan et al., 1996) . These MAPKs are activated by phosphorylation on threonine and tyrosine residues by a dual activity kinase MEK1 (Crews et al., 1992) . The dual activity kinase is, in turn, phosphorylated by the serine-threonine kinase c-Raf-1 (Huang et al., 1993; Kyriakis et al., 1992; Jelinek et al., 1994 ) the activity of which is determined by homodimerization (Farrar et al., 1996) , Ras (Kolch et al., 1991) , Protein Kinase C (Sozeri et al., 1992) and membrane phosphatases (Dent et al., 1995) . We show, for the ®rst time, that the elevated expression of the u-PAR gene in a colon cancer cell line (RKO) is largely a consequence of a constitutively activated ERK1-dependent signal transduction pathway.
Results

RKO cells, in which u-PAR display is elevated, contain a constitutively active ERK1
To determine the role of ERK1 and ERK2 in the regulation of u-PAR expression, the RKO and GEO colon cancer cell lines, which display 510 5 /cell and 10 4 receptors/cell respectively, were ®rst analysed for ERK activity. Immunoblotting of RKO and GEO cells extracts with an antibody, which crossreacts with ERK1 and ERK2, indicated ( Figure 1a ) the presence of immunoreactive proteins, which were indistinguish- Figure 1d ).
The expression of a MAPK-inactivating phosphatase, or a kinase-defective ERK1, reduces u-PAR promoter activity in RKO cells
To determine the causal role of the ERKs in the regulation of u-PAR expression, two experiments were then carried out. First, the eect of expressing an ERK-inactivating phosphatase (CL100) (Alessi et al., 1993; Keyse and Emslie, 1992) , on u-PAR promoter activity was determined. RKO cells were co-transfected with the u-PAR promoter-driven CAT reporter along with various amounts of an expression vector encoding the MAPK-inactivating phosphatase (CL100). CAT activity was reduced in a dose-dependent manner (Figure 2a ) by co-transfection of the cells with the MAPK-inactivating phosphatase-encoding expression vector (CL100a pSG5). An input of 10 mg of the CL100 expression construct diminished promoter activity by 80%. In contrast, an expression vector encoding a phosphatase-inactive CL100 (CL100i pSG5), or the empty expression vector (pSG5), had only a modest eect on u-PAR promoter activity. Expression of amounts of the MAPK phosphatase, which diminished u-PAR promoter activity, also reduced ( Figure 2b ) the activity of a CAT reporter driven by three tandem AP-1 repeats upstream of a thymidine kinase minimal promoter (36AP-1 pBLCAT). Second, RKO cells were transiently cotransfected with a u-PAR promoter-driven CAT PD 098059 (µM) Figure 3 The MEK1 inhibitor PD 098059 reduces u-PAR display in RKO cells. (a) and (b) Cells, at 90% con¯uency, were lysed with Triton X-100. For (a) the cell lysates (equal protein) were loaded onto a DE52-cellulose column. Aliquots of the¯ow through were incubated with a 72 kDa kinase-inactive ERK1-GST fusion protein bound to glutathione agarose beads and [g-32 P]ATP. The reaction was terminated with Laemmli sample buer and the mixture electrophoresed by SDS ± PAGE. Control represents a parallel incubation of the DE52-column equilibrating buer in the absence of cell extract. For (b) aliquots of the¯ow through were subjected to Western blotting using a polyclonal antibody which crossreacts with MEK1 and MEK2. (c) Cells extracts prepared as for (a), or authentic MEK1, were incubated with (+), or without (7), 2 mg of an anti-MEK1/MEK2 antibody (a-MEK Ab) and Protein A-agarose beads. The immunoprecipitated material was washed and incubated with 1 mg of the ERK1-GST fusion protein and [g-32 P]ATP at 308C. Reaction products were then resolved by SDS ± PAGE. (d) RKO cells were incubated for 4 days without (Control) or with the indicated concentrations of PD 098059 or an amount of DMSO (CARRIER) corresponding to the highest level of solvent used (0.05%). The cells were then treated for 3 min with a glycine buer and the acidic pH neutralized with a HEPES-containing buer (pH 7.4). The cells wre incubated at 48C for 2 h with 2.0 nM radioactive single chain urokinase (rscuPA) with, or without, a 100-fold excess of unlabeled ligand. The cells were subsequently washed and lysed with 1.0% Triton X-100. Speci®c binding was calculated by subtracting the amount of radioactivity bound in the presence of excess unlabeled ligand from that achieved in the absence and correcting for any dierences in cell number. The data represent the average values of two separate experiments. (e) RKO cells were treated for 48 h with the indicated concentration of PD 098059 or amounts of DMSO (CARRIER) corresponding to 10 mM of PD 098059. After this time, the cells were harvested, lysed and equal amounts of protein assayed for ERK activity as described in the legend to Figure 1 Regulation of u-PAR expression E Lengyel et al reporter and expression vectors encoding either a kinase-de®cient ERK1 or a kinase-de®cient ERK2. Expression of the mutated ERK1 (mt ERK1 pCEP 4 ) caused a dose-dependent repression of the u-PAR promoter with the highest amount of the expression construct resulting in approximately 65% inhibition (Figure 2c ). In contrast, the mutated ERK2 expression vector failed to down-regulate the u-PAR promoter in RKO cells this being consistent with the low ERK2 activity in these cells (Figure 1b, c) . The repression of u-PAR promoter activity by the ERK1 mutant was not due to a general inhibition of transcription since the activity of a CAT reporter driven by the RSV LTR (RSV CAT) was unaected.
A speci®c inhibitor of MEK1 activation decreases the cell surface binding of urokinase and laminin degradation by RKO cells
To determine if the elevated kinase activity corresponding to ERK1 in the u-PAR-overexpressing RKO cells was a consequence of a higher activity of an ERK activator, an ERK1-GST fusion protein was incubated with [g 32 P]ATP and extracts of either GEO or RKO cells eluted from a DE52 ion-exchange column. A greater amount of the ERK1-GST fusion protein was phosphorylated by the RKO cells over an identical incubation period (Figure 3a) . To determine the identity of the ERK activator, RKO and GEO extracts (or as a control authentic MEK1) were immunoprecipitated with an antibody which specifically recognizes (Figure 3b ) MEK1 and MEK2. The immunoprecipitated material was then incubated with [g 32 P]ATP and the ERK1-GST fusion protein. Over equivalent incubation periods, the immuno-complexes from RKO extracts phosphorylated more of the fusion protein than those generated with GEO extracts (Figure 3c ). These data suggest that the constitutive activation of ERK1 in RKO cells is largely a consequence of increased MEK1 and/or MEK2 activity.
We then determined the eect of PD 098059, which prevents the activation of MEK1 Alessi et al., 1995) , on u-PAR display. RKO cells were treated for 4 days with varying concentrations of the inhibitor, shown previously to inhibit MEK1 in cultured cells Alessi et al., 1995) , and assayed for cell surface urokinase binding after an acid pretreatment to dissociate endogenous receptorbound urokinase. PD 098059 reduced, in a dosedependent manner, the amount of urokinase bound to the cell surface (Figure 3d ). The highest concentration (10 mM) reduced radioligand binding by over 60%. The reduced amount of urokinase bound to the RKO cell surface re¯ected a diminished amount of u-PAR protein as determined by ELISA (data not shown). Analysis of ERK1 activity in PD 098059-treated RKO cells revealed an inhibition of this MAPK using concentrations of the MEK1 inhibitor which resulted in reduced binding of radioactive urokinase ( Figure  3e ). The concentrations of PD 098059 used did not aect the growth rate of RKO cells.
We then determined the eect of PD 098059 on extracellular matrix degradation. RKO cells were pretreated with PD 098059 for 4 days and plated on radioactive laminin-coated culture dishes. After cell attachment, surface receptors were saturated with exogenous urokinase. This step was undertaken to rule out the possibility that PD 098059 was repressing the synthesis of the endogenous plasminogen activator. Plasminogen was then added and the cultures incubated for 30 min. Aliquots of the culture medium Figure 4 Reduced laminin degradation by PD 098059-treated RKO cells. RKO cells were treated for 4 days with varying concentrations of PD 098059 or an amount (0.05% v/v) of DMSO carrier (PD 098059=0) equivalent to the highest concentration of the agent. The cells were harvested with EDTA and 500 000 seeded in the laminin-coated dishes in the presence, or absence, of PD 098059. After an overnight period to allow cell attachment, cell surface receptors were saturated with exogenous urokinase and unbound enzyme removed by washing. Plasminogen (10 mg/ml ®nal concentration) in serum-free medium was added and the cells cultured for 30 min at 378C. Aliquots of the culture medium were removed and counted for radioactivity. The experiment was carried out on four separate occasions. All data are corrected for the cell-independent release of the radioactive laminin (as observed with serum-free medium+plasminogen) which did not exceed 5000 c.p.m./well/30 min. The variation between experiments did not vary more than 15% Figure 5 Repression of u-PAR promoter activity by the expression of a kinase-inactive c-Raf-1. RKO cells were transiently transfected, as described in the legend to Figure 2 using a CAT reporter driven by the u-PAR promoter, a RSV luciferase expression construct, and the indicated amount (where 26 is a twofold molar excess of the eector plasmid relative to the reporter construct) of an expression vector encoding a kinasenegative c-Raf-1 protein (Raf C4) or the empty vector. Cell extracts, normalized for dierences in transfection eciencies, were assayed for CAT activity. The amount of [ 14 C]-chloramphenicol acetylated was calculated and expressed as a per cent of that achieved with an equivalent amount of the empty expression plasmid. The data represent an average of three separate experiments Regulation of u-PAR expressionwere harvested and counted for radioactivity. RKO cells did not solubilize laminin in the absence of plasminogen. However, in the presence of the zymogen, a dramatic solubilization of the extracellular matrix protein was observed (Figure 4) . Treatment of the cells with concentrations of PD 098059 (5 and 10 mM), which reduced ERK1 activity (see Figure 3e) , diminished laminin degradation. The highest concentration of PD 098059 (10 mM) reduced laminin degradation by approximately 60%.
The expression of a kinase-de®cient c-Raf-1 represses u-PAR promoter activity in RKO cells
Previous studies have demonstrated that MEK1 can be activated by the serine-threonine kinase c-Raf-1 (Huang et al., 1993; Kyriakis et al., 1992) . To determine the involvement of this serine-threonine kinase in the regulation of u-PAR expression, RKO cells were made to co-express a kinase-de®cient c-Raf-1 (Raf C4) and the u-PAR promoter-driven CAT reporter. RKO cells transfected with the Raf C4, demonstrated up to a 55% reduction in the activity of the u-PAR promoter-driven CAT reporter compared with cells made to express the empty expression vector ( Figure 5 ).
Stimulation of ERK1 is associated with increased u-PAR expression in GEO cells
Since our data suggested that interfering with ERK1 activity was repressive for u-PAR expression, we asked whether stimulation of ERK1 activity was associated with increased cell surface u-PAR display. To address this, two separate experiments were undertaken. First, the receptor-de®cient GEO cells were treated with a Cell surface binding of radioactive urokinase was analysed after an acid-pretreatment to dissociate endogenous plasminogen activator. The data are corrected for dierences in cell number. (b) At 80% con¯uency, the culture medium on GEO cells was either not changed or changed to fresh medium supplemented with the indicated concentrations of sodium vanadate. The cells were then incubated for a further 30 min. GEO cells were extracted and analysed for ERK activity using an in-gel kinase method as described in the legend to Figure 1b. (c) GEO cells were transfected as described in Figure 2 with a RSV-luciferase construct, a u-PAR promoter-driven CAT reporter (u-PAR CAT) and an expression construct encoding the wild type (MEK wt) or a constitutively activated MEK (MEK DN3S218E-S222D) where X is the molar amount of the eector plasmid relative to the reporter construct. Cell extracts were normalized for dierences in transfection eciency and assayed for CAT activity. pSV 0 CAT is a promoter-less CAT reporter construct. The experiments were performed at least twice
Regulation of u-PAR expression E Lengyel et al protein tyrosine phosphatase inhibitor (sodium vanadate) (Zhao et al., 1996) . GEO cells were then assayed for both ERK1 activity and cell surface binding of urokinase (Figure 6a,b) . Increasing concentrations of sodium vanadate caused a dose-dependent increase in the amount of radioactive urokinase bound to the GEO cell surface (Figure 6a ). The highest concentration of the phosphatase inhibitor (0.1 mM) increased radioligand binding about fourfold. ERK1 activity in untreated GEO cells was expectedly low but treatment with concentrations of sodium vanadate, which increased the amount of urokinase bound to the cell surface, caused a parallel increase in kinase activity (Figure 6b ). Since sodium vanadate is not speci®c towards ERK1, we next determined whether the expression of a constitutively activated MEK1 was inductive for u-PAR promoter activity. GEO cells were transfected with a u-PAR promoter-driven CAT reporter and varying amounts of a constitutively active MEK1 expression construct (MEK DN3S218E-S222D) (Mansour et al., 1994). The mutation-activated MEK1 was a potent inducer of u-PAR promoter activity in GEO cells. A molar equivalent of 0.016 of the eector plasmid doubled the u-PAR promoter activity in GEO cells (Figure 6c ). Increasing the amount of the MEK DN3S218E-S222D to 0.56 resulted in over a fourfold stimulation of u-PAR promoter activity. Neither the wild type nor the constitutively active MEK1 increased the activity of the promoter-less reporter construct (pSV 0 CAT). Thus, the stimulation of ERK1 by either a phosphatase inhibitor or by a natural upstream activator leads to increased u-PAR gene expression.
RKO cells do not contain a mutated K-Ras
Considering the ability of the kinase-defective c-Raf-1 expression construct to down-regulate u-PAR promoter activity and the well documented observation of KRas mutations in colon cancer (Bos, 1989) , we hypothesized that elevated u-PAR expression in RKO cells was a consequence of a mutation-activated K-Ras. However, PCR ampli®cation of codons 12 and 13 of K-Ras indicated the wild type seuqence in RKO cells. Likewise, codon 61 of K-Ras was not altered in RKO cells. The only K-Ras mutation detected was with u-PAR-de®cient GEO cells which contained a GGT (coding for glycine) to GCT (coding for alanine) substitution.
Discussion
The u-PAR accelerates plasmin formation at the cell surface and has been implicated in the invasiveness of a diverse set of tumor cell types including colon cancer (Quattrone et al., 1995; Kariko et al., 1993; Kook et al., 1994) . In resected colon cancer, elevated u-PAR expression, which portends a poor outcome (Ganesh et al., 1994) is observed in invasive tumors while normal crypt and stromal cells are negative for this binding protein (Wang et al., 1994; Pyke et al., 1991) . However, the mechanism(s) by which the u-PAR gene is overexpressed is unclear at the present time. Since phorbol ester and a variety of growth factors including EGF, FGF, and vEGF, which up-regulate u-PAR synthesis, stimulate ERK activity (Zohn et al., 1995; Wiese et al., 1995; Bogoyevitch et al., 1994; Campbell et al., 1995; Jones et al., 1994; Lund et al., 1995) , we undertook a study to determine the role of these MAPKs in regulating u-PAR expression in two cultured colon cancer cell lines. Several observations suggested a role for an ERK1-dependent signaling cascade in the regulation of u-PAR expression. First, the expression of either a dominant negative ERK1, or a MAPK-inactivating phosphatase (CL-100), downregulated u-PAR promoter activity in RKO cells in which ERK1 is constitutively activated. Second, treatment of RKO cells with PD 098059, which prevents the activation of MEK1, reduced the binding of radioactive urokinase to the cell surface and diminished laminin degradation by these cells. Third, u-PAR promoter activity was diminished by the expression of a kinase-de®cient c-Raf-1. Fourthly, stimulation of ERK1 activity in the receptor-de®cient GEO cells either by expressing a constitutively active MEK1 construct or with sodium vanadate was associated with increased u-PAR promoter activity and a larger amount of radioactive urokinase bound to the cell surface. Our data demonstrating a role for ERK1 in the regulation of u-PAR expression is reminiscent of other studies implicating this MAPK in the regulation of collagenase I gene expression and cellular transformation. Thus, Pages and co-workers found that the expression of a dominant negative ERK1 construct in the Chinese hamster lung ®broblast cell line CCL39 diminished the stimulation of type I collagenase promoter activity by ®broblast growth factor (Pages et al., 1993) . In a separate study, it was shown that the ability of Ras to transform NIH3T3 cells could be reduced by the co-expression of a dominant negative ERK1 (Khosravi-far et al., 1995) . Conversely, we saw little evidence that ERK2, which mediates, in part, AP-1 activation in REF-52 cells (Frost et al., 1994) , was involved in the regulation of u-PAR expression in RKO cells. Thus, RKO cells, which are high u-PAR expressors, contained little constitutively activated ERK2 and the expression of a plasmid encoding a dominant negative ERK2 failed to diminish u-PAR promoter activity.
It is conceivable that the ERK1-dependent regulation of u-PAR expression in RKO cells is mediated, at least in part, through either of the AP-1 motifs located at 7184 and 769 in the u-PAR promoter (Soravia et al., 1995) . ERK1 increases c-Fos expression (Gille et al., 1992) which in turn up-regulates Fra-1 synthesis (Bergers et al., 1995) . Additionally, there is evidence, albeit controversial, that indicates that the transactivating potential of cJun is increased by this MAPK (Pulverer et al., 1991; Agarwal et al., 1995; Bogoyevitch et al., 1995) . We recently showed that the AP-1 motif at 7184, which was required for elevated u-PAR expression in RKO cells as well as the phorbol ester-inducible expression in GEO cells, was bound with c-Fos, Fra-1, and c-Jun (Lengyel et al., 1996) . At the same time, it is equally possible that the regulation of u-PAR expression by ERK1 is achieved through other DNA-binding proteins such as PEA3 which has a consensus site in the u-PAR promoter (Soravia et al., 1995) and which is also a target for the ERK1 (O'Hagen et al., 1996) .
While our studies indicate that an activated ERK1-dependent signaling pathway contributes to the elevated u-PAR expression in RKO cells, the identity of the initial stimulus activating this signaling module is currently not known. ERK1 can be stimulated by the sequential activation of Ras-c-Raf-1-MEK1 (Kolch et al., 1991; Huang et al., 1993; Crews et al., 1992; Minden et al., 1994) . Indeed, the observations that u-PAR expression was reduced by interfering with MEK1 and c-Raf-1 is consistent with the notion that the initial stimulus lies upstream of c-Raf-1. Since K-Ras is inductive for u-PAR expression (Jankun et al., 1991) and since K-Ras mutations in colon cancer are well documented (Bos, 1989) , we initially speculated that a mutated K-Ras was the trigger for an activated ERK1-dependent signaling module in RKO cells. However, sequencing of codons 12, 13 and 61 of K-Ras revealed the wild type sequence thus ruling out this possibility. It is noteworthy that Oka and co-workers (Oka et al., 1995) made a similar observation with renal cell malignancies in that the tumors, which were also characterized by their constitutively activated ERK activity, did not manifest Ras mutations. While RKO cells did not contain a mutation-activated K-Ras, it is still possible that the activation of the ERK1-dependent signaling cascade is a consequence of Ras recruitment by a growth factoractivated receptor protein tyrosine kinase at the cell surface (Stacey et al., 1991) . Indeed, several studies have convincingly shown that a variety of growth factors including EGF (Lund et al., 1995) , vascular endothelial growth factor (vEGF) (Mandriota et al., 1995) and FGF (Pepper et al., 1993) all induce u-PAR expression. Alternatively, it is equally plausible that the constitutive activation of ERK1 in RKO cells is a consequence of (a) protein kinase C b stimulation (Sauma et al., 1996) , (b) a reduced activity/amount of K-Rev (Kitayama et al., 1989) , which is an endogenous inhibitor of Ras, or (c) lower activity/ amounts of phosphatases such as CL100, HVH2 or MKP-3 (Alessi et al., 1993; Guan and Butch, 1995; Muda et al., 1996) which function to return cells to the quiescent state (Dent et al., 1995) following their stimulation with growth factors.
In conclusion, the present study suggests that the elevated u-PAR expression in RKO cells is a consequence of a constitutively activated ERK1-dependent signaling module. Considering the evidence implicating the u-PAR in extracellular matrix degradation and tumor cell invasion/metastases (Quattrone et al., 1995; Kariko et al., 1993; Kook et al., 1994; Ganesh et al., 1994; Wilhelm et al., 1994) , these ®ndings raise the intriguing possibility that interfering with this pathway may provide a means of reducing u-PAR synthesis and extracellular matrix degradation in at least a sub-population of colon cancer.
Materials and methods
Vectors and antibodies
A 449 nucleotide u-PAR promoter fragment (Wang et al., 1995) stretching from 7398 to +51 (relative to the transcription start site) was cloned into the XbaI site of the pCAT-Basic vector (Promega, Madison, Wisconsin) . The CL100 expression vectors, kindly provided by SM Keyse, University of Dundee, UK, encodes an active (CL100a pSG5) or inactive (CL100i pSG5) CL100 phosphatase (Alessi et al., 1993; Keyse and Emslie, 1992) . The ERK1 and ERK2 constructs contain the coding region of these MAPKs in which the conserved lysine involved in phosphate transfer (codon 71 and 52 for ERK1 and ERK2 respectively) has been changed to arginine thus impairing the catalytic eciency (Frost et al., 1994) . The Raf C4 expression plasmid encodes the c-Raf-1 protein lacking the kinase domain (Bruder et al., 1992) . The MEK DN3S218E-S222D construct encodes the MEK1 sequence in which residues 32 ± 51 at the aminoterminus have been deleted and in which the serines at position 218 and 222 have been replaced by glutamate and aspartate respectively (Mansour et al., 1994) . The 36AP1 pBLCAT construct consists of three AP-1 tandem repeats upstream of a thymidine kinase mininal promoter-CAT reporter (pBLCAT) (Angel et al., 1988) .
Transfections RKO cells were transfected by a calcium phosphate method (Lengyel et al., 1996) as described previously but with minor modi®cations. All transient transfections were performed in the presence of 5 mg of a luciferase expression vector to correct for dierences in transfection eciencies. Brie¯y, DNA precipitate formed in the presence of 124 mM calcium chloride in a buer containing 15 mM HEPES (pH 7.1), 280 mM NaCl and 1.5 mM Na 2 HPO 4 was added to 50% con¯uent cells. After 5 h, the cells were shocked for 3 min with 25% glycerol and changed to fresh 10% FBS-containing medium. GEO cells were transfected using poly-L-ornithine as described previously (Nead and McCance, 1995) . Essentially, the cells were incubated with DNA and 31 mg poly-L-ornithine (Sigma Chemicals, St Louis, MO). After 6.5 h, the cells were shocked as described for RKO cells. After 48 h, all cells were harvested and lysed by repeated freeze-thaw cycles in a buer containing 0.25 M Tris-Cl pH 7.8. Transfection eciencies were determined by assaying for luciferase activity. CAT activity was measured by incubating cell lysates (normalized for transfection eciency) at 378C for 6 h with 4 mM [ 14 C]chloramphenicol and 1 mg/ml acetyl Coenzyme A. After 3 h, the acetyl Coenzyme A was replenished. The mixture was extracted with ethyl acetate and acetylated products subjected to thin layer chromatography using chloroform: methanol (95 : 5) as a mobile phase. The amount of acetylated [ 14 C]chloramphenicol was determined using a 603 Betascope.
ERK assays
Assays for ERK activity were carried out as described elsewhere (Morino et al., 1995) but with minor modifications (Lengyel et al., 1995) . Brie¯y, cells were extracted with buer A (1% NP-40, 25 mM Tris-HCl, pH 7.4, 25 mM NaCl, 1 mM sodium vanadate, 10 mM NaF, 10 mM sodium pyrophosphate, 10 nM okadaic acid, 0.5 mM EGTA, and 1 mM PMSF). Insoluble material was removed by centrifugation at 14 000 g for 10 min and the supernatants assayed for protein content. Cell extracts, containing an equal amount of protein, were incubated at 48C for 1 h simultaneously with 0.5 mg of the anti-ERK antibody (Santa Cruz Biotechnology #93) and Protein-A agarose beads. The beads were washed with 1% Nonidet P-40 lysis buer, resuspended in 36 sample buer, and the immune complexes electrophoresed in an SDS-polyacrylamide gel containing 0.5 mg/ml myelin basic protein (MBP). SDS was removed from the gel with two changes of 20% 2-propanol in 50 mM Tris-HCl (pH 8.0) and then with 50 mM Tris-HCl containing 5 mM 2-mercaptoethanol. The proteins were ®rst denatured by treating the gel with two changes of 6 M guanidine HCl and then renatured overnight with 50 mM Tris-HCl (pH 8.0) containing 0.04% Tween 40 and 5 mM 2-mercaptoethanol. After renaturation, the gel was preincubated at 258C for 1 h with a 40 mM HEPES (pH 8.0) solution containing 2 mM dithiothreitol, 0.1 mM EGTA and 5 mM MgCl 2 . Phosphorylation of MBP was carried out by incubating the gel at 258C for 1 h in the same buer supplemented with 40 mM ATP, and 25 mCi of [g 32 P]ATP. After incubation, the gel was washed thoroughly in a solution containing 5% TCA and 1% sodium pyrophosphate then dried and autoradiographed.
Assay for ERK activators
ERK activators were measured as described previously (Ohmichi et al., 1993; Shirakabe et al., 1992) . Cells were lysed in a solution of a buer containing 50 mM bglycerophosphate, 10 mM Tris-Cl (pH 7.5), 70 mM NaCl, 1% Triton X-100 and 4 mg/ml leupeptin. The ERK activators were either immunoprecipitated with an anti-MEK1/MEK2 antibody (Transduction Laboratories #M17030) or separated from endogenous ERKs by ionexchange chromatography on a DE 52-cellulose column equilibrated with a buer (20 mM Tris-Cl (pH 7.5), 25 mM b-glycerophosphate, 2 mM EGTA, 2 mM PMSF, 20 mg/ml aprotinin, 2 mM DTT and 1 mM sodium vanadate) containing 100 mM NaCl. The¯ow-through or immunoprecipitated material was assayed for ERK activators in a buer containing 20 mM Tris-Cl (pH 7.5), 10 mM MgCl 2 , 1 mM MnCl 2 , 1 mM EGTA, [g 32 P]ATP and a kinaseinactive ERK1-GST fusion protein (20 mg) (which for the DE52¯ow-through was bound to glutathione agarose beads). (Mr 72 kDa) (kindly provided by Steven Pelech, Kinetek Biotechnology Corp, Vancouver, Canada). After incubation for 30 min at 308C, the reaction was terminated with Laemmli sample buer and the proteins separated by 7.5% SDS ± PAGE.
Western blotting for ERK1, ERK2, MEK1 and MEK2
Brie¯y, cell extracts were denatured in the absence of reducing agent and proteins separated by 12.5% SDS ± PAGE. The resolved proteins were transferred to a nitrocellulose ®lter. The ®lter was blocked with 3% BSA and incubated with polyclonal antibodies reactive with human ERK1 and ERK2 (Santa Cruz Biotechnology #93) or with MEK1 and MEK2 (Transduction Laboratories #M17030). Subsequently, the blot was incubated with horseradish peroxidase-conjugated anti-rabbit IgG and immunoreactive bands visualized by ECL as described by the manufacturer (Amersham, Arlington Heights, IL).
Radioligand binding assays
These were performed as described previously (Boyd et al., 1988) but with minor modi®cations. Brie¯y, 90 ± 100% con¯uent cells were pretreated with an acid buer (50 mM glycine pH 3.0, 0.1 M NaCl) for 3 min followed by a solution containing 50 mM HEPES (pH 7.4). The cells were washed and then incubated at 48C for 2 h with 2.0 nM radioactive single chain urokinase (proenzyme) in the presence, or absence, of a 100-fold excess of unlabeled urokinase. After this time, the cells were washed extensively with PBS containing 0.1% BSA and lysed with a 1% Triton X-100-containing solution. Cell number was determined in a parallel set of dishes. The amount of radioactive urokinase speci®cally bound was calculated by subtracting the background level observed in the presence of unlabeled ligand. Data are expressed after correcting for dierences in cell number.
Detection of point mutations in K-Ras
This was carried out essentially as described previously (Ridanpaa and Husgafvel-Pursiainen, 1993 ) but with minor modi®cations. Genomic DNA was extracted using a Midi Kit from Qiagen (Chatsworth, California) as instructed by the manufacturer. The DNA spanning codons 12 and 13 was ampli®ed by the polymerase chain reaction using the following forward and reverse primers respectively: AGGCCTGCTGAAAATGACTG and GTCCTGCAC-CAGTAATATGC. A total of 27 ampli®cation cycles was used with denaturing, annealing, and extension temperatures of 96, 65 and 728C respectively. Subsequently, the ampli®ed products were resolved in a 1.5% agarose gel, the 163 base pair band extracted using the QIAquick gel extraction kit (Qiagen, Chatsworth, California) and sequenced directly with a Sequenase DNA sequencing kit (Amersham, Arlington Heights, IL).
Determination of growth rates
Cells (50 000) were plated out in 25 cm 2 dishes. At the indicated times, the cells were incubated with MTT for 3 h with 0.2 mg/ml MTT. Crystals were solubilized with DMSO and color intensity read at 570 nm (Mossman, 1983) .
Laminin degradation assays
These were carried out as described previously (Schlechte et al. 1989) . Brie¯y, laminin was radiolabeled with Na 125 I using a chloramine-T method. After extensive dialysis to remove unincorporated iodide, the radioactive laminin was coated onto 23 mm dishes (2 mg/dish). RKO cells were harvested with 3 mM EDTA, washed twice and seeded (500 000 cells) in the radioactive laminin-coated dishes. The cells were allowed to attach overnight in the presence, or absence, of PD 098059. Subsequently, cell surface u-PAR were saturated by incubating the cells at 378C for 30 min with 5 nM urokinase and unbound plasminogen activator removed by washing. The cells were then replenished with serum-free medium with, or without, 10 mg/ml plasminogen (®nal concentration). After a 30 min incubation at 378C, aliquots of the culture medium were withdrawn and counted for radioactivity. We previously showed that solubilized laminin represented proteolytic fragments of the glycoprotein (Schlechte et al., 1989) .
